Financials data is unavailable for this security.
View more
Year on year Bio Rad Laboratories Inc had revenues fall -4.67% from 2.80bn to 2.67bn, though the company grew net income from a loss of 3.63bn to a smaller loss of 637.32m.
| Gross margin | 54.43% |
|---|---|
| Net profit margin | -30.18% |
| Operating margin | 11.86% |
| Return on assets | -6.92% |
|---|---|
| Return on equity | -9.79% |
| Return on investment | -7.26% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Bio Rad Laboratories Inc fell by 30.18m. However, the company earned 374.94m from its operations for a Cash Flow Margin of 14.04%. In addition the company generated 20.21m cash from investing, though they paid out 425.65m more in financing than they received.
| Cash flow per share | -22.13 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 267.46 |
|---|---|
| Tangible book value per share | 241.66 |
More ▼
Balance sheet in USDView more
| Current ratio | 6.14 |
|---|---|
| Quick ratio | 4.52 |
| Total debt/total equity | 0.1604 |
|---|---|
| Total debt/total capital | 0.1383 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 82.08%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -391.52 |
